About half of people with gout don't have treatments that work. Meet the new gout drugs racing through trials to reach them.

The only TIL therapy approved so far is Amtagvi for melanoma. Here are six companies with promising TIL therapies in the ...

Roche's AXELIOS 1 enters next generation DNA sequencing. Can it or rivals unseat Illumina's long-standing market dominance?

With 10 cases in 2025, Guinea worm could be the second disease ever eradicated. Here is what makes disease eradication ...

Delve into what Merck has planned for the future of its pipeline as Keytruda's patent is getting closer to expiry.

Scientists, biochemists, and R&D leaders in pharma and biotech seeking to harness AI to drive innovation, improve efficiency, and stay ahead in drug development. He is the author of two books and 11 ...

Human immunodeficiency virus (HIV) research has come a long way since the virus was discovered in the 1980s. Antiretroviral therapy (ART) marked a turning point in HIV treatment, changing the lives of ...

The biggest acquisition deal announced in June was by pharma giant AbbVie. Known for its monoclonal antibodies Humira and Skyrizi, for autoimmune diseases, AbbVie plans to buy Massachusetts-based ...

Bipolar disorder disrupts daily life, causing severe shifts in mood and energy, flipping between extreme highs and deep lows. Most patients who are prescribed currently available drugs for the ...

With a major restructuring underway, Japanese pharma giant Takeda is entering a defining period for its business. Having completed years of portfolio reshaping following its acquisition of Shire in ...

First, let’s take a look at the private biotech investments in June 2026, breaking them down by value, location, funding type, and therapeutic subsector. Last month, NewLimit was the company to raise ...